ПАЛОНОСЕТРОН В ПРОФИЛАКТИКЕ ТОШНОТЫ И РВОТЫ ПРИ ПРОВЕДЕНИИ ВЫСОКО И УМЕРЕННО ЭМЕТОГЕННОЙ ХИМИОТЕРАПИИ
- Авторы: Абрамов М.Е1, Лодыгина К.С2
-
Учреждения:
- ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва
- ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России, Москва
- Выпуск: № 8 (2014)
- Страницы: 29-34
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/286926
- ID: 286926
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Тошнота и рвота - одни из наиболее часто возникающих осложнений химиотерапии. Антагонисты 5-НТ3-рецепторов являются основной группой препаратов для терапии и профилактики тошноты и рвоты. Оницит® (палоносетрон) - новый, высокоэффективный селективный антагонист 5-НТ3-рецепторов второго поколения, обладающий высоким сродством к рецептору и длинным периодом полувыведения (~40 часов). Исходя из данных опубликованных ключевых сравнительных исследований III фазы, а также рекомендаций MACSS, ESMO, NCCN, ASCO, палоносетрон в комбинации с антагонистом NK-I-рецепторов и дексаметазоном рекомендуется для профилактики тошноты и рвоты при проведении высоко- и среднеэметогенной химиотерапии.
Полный текст
Об авторах
М. Е Абрамов
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москвак.м.н., с.н.с.
К. С Лодыгина
ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России, Москваординатор кафедры онкологии и лучевой терапии
Список литературы
- Hesketh P.J. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999; 4: 191-96.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology-Antiemesis. 2005; 1.
- Multinational Association of Supportive Care in Cancer (MASCC). 2004 Perugia Antiemetic Consensus Guidelines. Support Care Cancer. 2005; 13: 77-131
- Gregory R.E., Ettinger D.S. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs. 1998; 55: 173-89
- Johnston D., Latrielle J., Laberge F., et al. Preventing nausea and vomiting during days 2-7 following high-dose cisplatin chemotherapy (HDCP). A study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Proc. Am. Soc. Clin. Oncol. 1995; 14: 529. (abstr).
- Grunberg S.M., Deuson R.R., Mavros P., et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004; 100: 2261-68.
- Hickok J.T., Roscoe J.A., Morrow G.R., et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. A University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 Cancer Patients Treated in the Community. Cancer. 2003; 97: 2880-86.
- Kaizer L., Warr D., Hoskins P., et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emeto-genic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1994; 12: 1050-57.
- Osoba D., Zee B., Warr D., et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 1997; 5: 307-13.
- Wong E.H.F., Clark R., Leung E., et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br. J. Pharmacol. 1995; 114: 851-59.
- Stoltz R., Cyong J.C., Shah A., et al. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J. Clin. Pharmacol. 2004; 44: 520-31.
- Roscoe J.A., et al. Patient expectation is a strong predictor of severe nausea after chemotherapy. Cancer. 2004; 101: 2701.
- Gralla R., Lichinitser M., Van Der Vegt S., et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003; 14(10): 1570-77.
- Eisenberg P., Figueroa-Vadillo J., Zamora R., et al. 99-04 Palonosetron Study Group Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III., single-dose trial versus dolasetron. Cancer. 2003; 98(11): 2473-82.
- Aapro M.S., Bertoli L., Lordic F., et al. Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy [abstract A-17]. Support Care Cancer. 2003; 11(6): 391.
- Clark O., Engel T., Clark L., et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatments: Systematic review and meta-analysis. J. Clin. Oncol. 2009; 27(suppl): abstr e20620.
- Efficacy of palonosetron-based antiemetic prophylaxis in breast cancer patients receiving anthracycline-containing adjuvant chemotherapy: A survey in 41 German gyneco-oncology practices. J. Clin. Oncol. 2012; 30(suppl): abstr. e19540.
- Giralt J., et al. Oncol. Pharm Pract. September 4, 2013 1078155213502103.
- Deauna-Limayo D., Aljitawi O.S., Siddhartha Ganguly, et al. Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study Bernardo G., Palumbo R., Frascaroli M., Bernardo A., Losurdo A., Poggi G., Teragni C., Albanese D., Amatu A., Strada M.R. Palonosetron compared to ondansetron in the prevention of chemotherapy-induced nausea and vomiting: Activity, safety, and cost-effectiveness evaluation. J. Clin. Oncol. 2009; 27(suppl): abstr. e20573.
- Kim S.K., Choi Y.J., Seol Y.M., Song M.G., Shin H.J., Chung J., Cho G.J. Efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with stomach cancer receiving FOLFOX4 regimen. J. Clin. Oncol. 2011; 29(suppl): abstr e19580.
- Blazer M.A., Reardon J., Efries D., et al. Antiemetic control of palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen containing either irinotecan or oxaliplatin. J. Clin. Oncol. 2011; 29(suppl): abstr. 9079.
Дополнительные файлы
